References
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 [displayed 14 September 2023]. Available at https://www.ncbi.nlm.nih.gov/books/NBK423845/
- Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B, Márquez J. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett 2017;13:4002–12. doi: 10.3892/ol.2017.6016
- Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Canc Treat Rev 2008;34:656–69. doi: 10.1016/j.ctrv.2008.05.002
- Velasco G, Hernández-Tiedra S, Dávila D, Lorente M. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:259–66. doi: 10.1016/j.pnpbp.2015.05.010
- Guzmán M. Cannabis for the management of cancer symptoms: THC Version 2.0? Cannabis Cannabinoid Res 2018;3:117–9. doi: 10.1089/can.2018.0009
- Cinnamon Bidwell L, York Williams SL, Mueller RL, Bryan AD, Hutchison KE. Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. Addict Behav Rep 2018;8:102–6. doi: 10.1016/j.abrep.2018.08.004
- Mathijssen RHJ, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182–94. PMID: 11489791
- Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752–7. PMID: 8706020
- Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–59. doi: 10.2165/00003088-200342040-00003
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770–804. doi: 10.1002/cbdv.200790152
- Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006;20:163–75. doi: 10.1016/j.tiv.2005.06.045
- Holland ML, Lau DTT, Allen JD, Arnold JC. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 2007;152:815–24. doi: 10.1038/sj.bjp.0707467
- Bouquié R, Deslandes G, Mazaré H, Cogné M, Mahé J, Grégoire M, Jolliet P. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. Fundam Clin Pharmacol 2018;32:462–84. doi: 10.1111/fcp.12373
- Kopjar N, Fuchs N, Brčić Karačonji I, Žunec S, Katić A, Kozina G, Lucić Vrdoljak A. High Doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions. Clin Drug Investig 2020;40:775–87. doi: 10.1007/s40261-020-00954-y
- Prester L, Mikolić A, Jurič A, Fuchs N, Neuberg M, Lucić Vrdoljak A, Brčić Karačonji I. Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats. Chem Biol Interact 2018;294:128–34. doi: 10.1016/j.cbi.2018.08.009
- Lucić Vrdoljak A, Fuchs N, Mikolić A, Žunec S, Brčić Karačonji I, Jurič A, Prester Lj, Micek V, Neuberg M, Čanović S, Mršić G, Kopjar N. Irinotecan and Δ9-tetrahydrocannabinol interactions in rat liver: a preliminary evaluation using biochemical and genotoxicity markers. Molecules 2018;23:1332. doi: 10.3390/molecules23061332
- Zakon o zaštiti životinja [Animal protection act, in Croatian]. Službeni list 102/2017.
- ARRIVE. The ARRIVE guidelines 2.0 [displayed 14 September 2023]. Available at https://arriveguidelines.org/sites/arrive/files/documents/ARRIVE%20guidelines%202.0%20-%20English.pdf
- Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes [displayed 14 September 2023]. Available at https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF
- Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res 1999;19:2269–74. PMID: 10472342
- Hardman WE, Moyer MP, Cameron IL. Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983–8. doi: 10.1038/sj.bjc.6600175
- Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998;42:165–70. doi: 10.1007/s002800050801
- Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011;50:600–13. PMID: 22330705
- Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 1998;4:455–62. PMID: 9516936
- Loflin M, Earleywine M. A new method of cannabis ingestion: The dangers of dabs? Addict Behav 2014;39:1430–3. doi: 10.1016/j.addbeh.2014.05.013
- Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Invest Drugs 2008;9:65–75. PMID: 18183533
- Bridgeman MB, Abazia DT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharm Ther 2017;42:180–8. PMID: 28250701
- Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR, editor. Biochemistry and physiology of substance abuse. Boca Raton (FL): CRC Press; 1991. p. 279–365.
- Rella JG. Recreational cannabis use: pleasures and pitfalls. Cleve Clin J Med 2015;82:765–72. doi: 10.3949/ccjm.82a.14073
- Goullé JP, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr 2008;66:232–44. doi: 10.1016/j.pharma.2008.07.006
- Schwilke EW, Schwope DM, Karschner, EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55:2180–9. doi: 10.1373/clinchem.2008.122119
- McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10:15A–22A. doi: 10.1155/2005/242516
- Kim HJ, Kim SJ, Woo CW, Kim ST, Im M, Park SK, Kim JY, Yoo HJ, Woo DC, Kim JK. Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study. Metabolomics 2021;17(4):36. doi: 10.1007/s11306-021-01781-8
- ARENA/OLAW. Institutional Animal Care and Use Committee Guidebook, 2002 [displayed 14 September 2023]. Available at https://olaw.nih.gov/sites/default/files/GuideBook.pdf
- Rodriguez-Gonzalez JC, Hernández-Balmaseda I, Declerck K, Pérez-Novo C, Logie E, Theys C, Jakubek P, Quiñones-Maza OL, Dantas-Cassali G, Carlos Dos Reis D, Van Camp G, Lopes Paz MT, Rodeiro-Guerra I, Delgado-Hernández R, Vanden Berghe W. Antiproliferative, antiangiogenic, and antimetastatic therapy response by mangiferin in a syngeneic immunocompetent colorectal cancer mouse model involves changes in mitochondrial energy metabolism. Front Pharmacol 2021;12:670167. doi: 10.3389/fphar.2021.670167
- Kašuba V, Tariba Lovaković B, Lucić Vrdoljak A, Katić A, Kopjar N, Micek V, Milić M, Pizent A, Želježić D, Žunec S. Evaluation of toxic effects induced by sub-acute exposure to low doses of α-cypermethrin in adult male rats. Toxics 2022;10:717. doi: 10.3390/toxics10120717
- Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9
- Katalinić M, Maček Hrvat N, Zdarova Karasová J, Misik J, Kovarik Z. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning. Arh Hig Rada Toksikol 2015;66:291–8. doi: 10.1515/aiht-2015-66-2740
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8. doi: 10.1016/0003-2697(79)90738-3
- Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol 1999;155:109–17. doi: 10.1006/exnr.1998.6969
- Kamencic H, Lyon A, Paterson PG, Juurlink BH. Monochlorobimane fluorometric method to measure tissue glutathione. Anal Biochem 2000;286:35–7. doi: 10.1006/abio.2000.4765
- Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, Ryuge S,Wada M, Onoda S, Yanaihara T, Yokoba M, Mitsufuji H, Nishii Y, Fukui T, Masuda N. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 2008;20:727–30. PMID: 18813810
- Houghton PJ, Cheshire PJ, Hallman Jr JD, Lutz L, Friedman HS, Danks MK, Houghton JA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393–403. doi: 10.1007/BF00686188
- Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ. Efficacy of systematic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423–31. PMID: 9815701
- Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM. Δ9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000;165:373–80. doi: 10.4049/jimmunol.165.1.373
- Zhong W, Myers JS, Wang F, Wang K, Lucas J, Rosfjord E, Lucas J, Hooper AT, Yang S, Lemon LA, Guffroy M, May C, Bienkowska JR, Rejto PA. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics 2020;21(1):2. doi: 10.1186/s12864-019-6344-3
- Montenegro MF, Nieto-Cero´n S, Ruiz-Espejo F, de la Cadena MP, Rodriguez-Berrocal FJ, Vidal CJ. Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chem Biol Interact 2005;157–8:429–30. doi: 10.1016/j.cbi.2005.10.091
- Vidal CJ. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact 2005;15–8:227–32. doi: 10.1016/j.cbi.2005.10.035
- Battisti V, Bagatini MD, Maders LD, Chiesa J, Santos KF, Gonçalves JF, Abdalla FH, Battisti IE, Schetinger MR, Morsch VM. Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis. Biomed Phar macother 2012;66:249–55. doi: 10.1016/j.biopha.2011.11.005
- Kimura S, Soria F, D’Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, Shariat SF, Gust KM. Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2018;16(6):e1123–32. doi: 10.1016/j.clgc.2018.07.002
- Dodds HM, Bishop JF, Rivory LP. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst 1999;91:91–2. doi: 10.1093/jnci/91.1.91a
- Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda K. A molecular link between the active component of marijuana and Alzheimer disease patologhy. Mol Pharm 2006;3:773–7. doi: 10.1021/mp060066m
- Perillo B, Di Donato M, Pezone, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med 2020;52:192–203. doi: 10.1038/s12276-020-0384-2
- Pavlek LR, Dillard J, Rogers LK. The role of oxidative stress in toxicities due to drugs of abuse. Curr Opin Toxicol 2020;20–21:29–35. doi: 10.1016/j.cotox.2020.04.003
- Rtibi K, Selmi S, Grami D, Sebai H, Amri M, Marzouki L. Irinotecan chemotherapy-induced intestinal oxidative stress: Underlying causes of disturbed mucosal water and electrolyte transport. Pathophysiology 2017;24:275–9. doi: 10.1016/j.pathophys.2017.07.002